MGMT was one of the first predictive DNA methylation biomarkers to determine a patient’s response to alkylating chemotherapeutics and it was shown that glioblastoma patients with tumor MGMT promoter methylation have a survival benefit from Temozolomide chemotherapy [120,121]. This evidence concerns the gene MGMT and glioblastoma.